Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravir

Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravir Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI). https://ift.tt/eA8V8J